Patient characteristics
| . | Control (n = 279)* . | Intervention (n = 277)* . |
|---|---|---|
| Male/female, n | 191/88 | 188/89 |
| Age, mean ± SD, y | 54 ± 12 | 54 ± 12 |
| Body surface area, mean ± SD, m2 | 1.97 ± 0.25 | 2.00 ± 0.24 |
| Enlarged spleen, n (%) | 17 (6.1)† | 31 (11) |
| Multiple inclusions, n (%) | 57 (20) | 39 (14) |
| Diagnosis, n (%) | ||
| AML | 132 (47.3) | 133 (48.0) |
| Acute lymphoblastic leukemia | 25 (9.0) | 24 (8.7) |
| Mantle cell lymphoma | 13 (4.7) | 14 (5.1) |
| Non-Hodgkin lymphoma | 41 (15.0) | 38 (13.7) |
| Multiple myeloma | 43 (15.0) | 45 (16.2) |
| Chronic leukemia | 3 (1.1) | 0 (0) |
| Other | 22 (7.9) | 23 (8.3) |
| Treatment, n (%) | ||
| Remission induction chemotherapy | 119 (42.7) | 116 (41.9) |
| Consolidation chemotherapy | 32 (11.5) | 35 (12.6) |
| Autologous stem cell transplantation | 101 (36.2) | 103 (37.2) |
| Allogeneic stem cell transplantation | 25 (8.9) | 16 (5.8) |
| Other | 2 (0.7) | 7 (2.5) |
| Laboratory values at randomization, mean ± SD | ||
| Platelet count, 109/L | 87 ± 100 | 79 ± 75 |
| Hemoglobin, g/L | 81 ± 29 | 82 ± 24 |
| Activated partial thromboplastin time, s | 29 ± 7.9 | 29 ± 8.7 |
| Prothrombin time, s | 12 ± 2.2 | 12 ± 1.9 |
| Fibrinogen, g/L | 3.7 ± 1.3 | 3.6 ± 1.4 |
| Medication and medical history, n (%) | ||
| Anticoagulant/antiplatelet therapy | 30 (10.8) | 31 (11) |
| Bleeding | 67 (24) | 72 (26) |
| Infection | 26 (9.3) | 27 (10) |
| Prior platelet transfusion | 181 (67) | 162 (60) |
| Prior red cell transfusion | 197 (71) | 191 (69) |
| Prior stem cell transplant procedure | 22 (7.9)† | 9 (3.2) |
| Prior pregnancy | 61 (22) | 66 (24) |
| . | Control (n = 279)* . | Intervention (n = 277)* . |
|---|---|---|
| Male/female, n | 191/88 | 188/89 |
| Age, mean ± SD, y | 54 ± 12 | 54 ± 12 |
| Body surface area, mean ± SD, m2 | 1.97 ± 0.25 | 2.00 ± 0.24 |
| Enlarged spleen, n (%) | 17 (6.1)† | 31 (11) |
| Multiple inclusions, n (%) | 57 (20) | 39 (14) |
| Diagnosis, n (%) | ||
| AML | 132 (47.3) | 133 (48.0) |
| Acute lymphoblastic leukemia | 25 (9.0) | 24 (8.7) |
| Mantle cell lymphoma | 13 (4.7) | 14 (5.1) |
| Non-Hodgkin lymphoma | 41 (15.0) | 38 (13.7) |
| Multiple myeloma | 43 (15.0) | 45 (16.2) |
| Chronic leukemia | 3 (1.1) | 0 (0) |
| Other | 22 (7.9) | 23 (8.3) |
| Treatment, n (%) | ||
| Remission induction chemotherapy | 119 (42.7) | 116 (41.9) |
| Consolidation chemotherapy | 32 (11.5) | 35 (12.6) |
| Autologous stem cell transplantation | 101 (36.2) | 103 (37.2) |
| Allogeneic stem cell transplantation | 25 (8.9) | 16 (5.8) |
| Other | 2 (0.7) | 7 (2.5) |
| Laboratory values at randomization, mean ± SD | ||
| Platelet count, 109/L | 87 ± 100 | 79 ± 75 |
| Hemoglobin, g/L | 81 ± 29 | 82 ± 24 |
| Activated partial thromboplastin time, s | 29 ± 7.9 | 29 ± 8.7 |
| Prothrombin time, s | 12 ± 2.2 | 12 ± 1.9 |
| Fibrinogen, g/L | 3.7 ± 1.3 | 3.6 ± 1.4 |
| Medication and medical history, n (%) | ||
| Anticoagulant/antiplatelet therapy | 30 (10.8) | 31 (11) |
| Bleeding | 67 (24) | 72 (26) |
| Infection | 26 (9.3) | 27 (10) |
| Prior platelet transfusion | 181 (67) | 162 (60) |
| Prior red cell transfusion | 197 (71) | 191 (69) |
| Prior stem cell transplant procedure | 22 (7.9)† | 9 (3.2) |
| Prior pregnancy | 61 (22) | 66 (24) |